In the future, case-control as well as longitudinal studies involving sufficient numbers of participants with a longer follow-up period and repeated measurements of plasma NfL will be necessary to confirm our findings and promote the clinical application of the biomarker-supported diagnosis of dementia in DS patients. This evidence concerns the gene NEFL and Dravet syndrome.